On-site Preventive Care Market to Grow at CAGR of 7.1% through 2027

Future Market Insights has published a new report titled “On-site Preventive Care Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027).” The report states that the standards set in the workplace for the safety of workers and the need to adhere to workplace norms have triggered the demand for on-site preventive care. Moreover, the increasing incidences of workplace illness has also made it an obligation for employers to follow employee safety codes and adopt on-site preventive care. As a result, the global on-site preventive care market is expected to witness a CAGR of 7.1% from 2017 to 2027. The market was worth around US$ 16,135 Mn in 2017 and is likely to touch a valuation of US$ 32,063 Mn approximately by the end of 2027.

On-site clinics enable employees to receive the required essential care at the time of emergency without having to leave the workplace. The clinicians in these clinics also aid employees in searching for a primary care physician who they can consult with on a regular basis. As a Future Market Insights analyst quotes, “Changes in lifestyle among the working class have incessantly impelled employers to establish certain behavioural standards within the workplace. This is one of the core factors responsible for the growing adoption of on-site preventive care in several organisations across the globe.”

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5518

Burgeoning Penetration of Workplace Wellness Programmes to Bode Well for the Market

In the recent past, workplace wellness programmes have earned the merit of being one of the most adopted healthcare services in the world. It has been further expected that its adoption will increase in the coming years owing to the implementation of the Affordable Care Act. This act is expected to promote an increase in the employee-based coverage of workplace wellness and also promote these programmes through several provisions. Moreover, the growing incidences of chronic diseases among the working population have also become a matter of concern and this has compelled employers across the globe to adopt as well as promote workplace wellness programmes.

Furthermore, employers who have adopted on-site preventive care services have reported enhanced performance ranging from heightened morale and cost savings to productivity. The death of time, access, and cost along with misunderstanding of the benefits of prescribed wellness programmes result in the underutilisation of primary care services. As a result, employees flood emergency rooms, missing out on critical preventive care measures and also leave chronic conditions go unmanaged. In this regard, on-site clinics provide employees with the necessary support without having to leave their work and plus the clinicians also work together with the patients in a cohesive environment to address their various health related issues.

North America and Western Europe to Compete Neck and Neck

In 2017, North America held a share of 37.0% in the global on-site preventive care market closely trailed by Western Europe. The dominance of North America can be attributed to the several policies implemented by the U.S. government pertaining to employee safety and the adoption of certain employee codes of safety. The U.S. is also an extremely mature market owing to the high adoption of workplace wellness programmes.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-5518

Companies to Innovate Services in the Global Market

In order to stay ahead of the competition, several companies operating in the global market are focussing on innovating their existing services and integrating new services. Some of the leading companies in the market are Premise Health, OnSite Care, Inc., PrevMED, RepuCare, Healthcare Solutions Centers, LLC, McCormack & Kale Motiva Health & Chiropractic, Inc., Marino Wellness, Kinema Fitness, and TotalWellness.

Rare Neurological Disease Treatment Market Size Projected to Rise Lucratively during 2017-2026

According to a newly published Future Market Insights report, the global rare neurological disease treatment market will exhibit a splendid expansion throughout the forecast period (2017-2026). Revenues from the market are envisaged to exceed US$ 12,000 Mn by 2026-end.

New Drug Formulations and Initiatives toward Improving Treatment & Care of Patients to Influence Market Growth

Declining blockbuster drugs have led pharmaceutical companies to keenly investigate potential new areas of research & development. Drug manufacturers have been incentivized by the Orphan Drug Act to develop new drug formulations associated with treatment of various rare diseases such as rare neurological diseases, in a bid to introduce new treatment options to the market. Regulatory advantages such as breakthrough designations, longer market exclusivity, and reduced fees & tax incentives have encouraged investments in R&D of drugs related to rare neurological diseases.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6445

The world is entering into a new era, wherein science has realized the capability of aiding development of treatment & care for patients affected with rare neurological conditions. Several initiatives are being taken for coordinating efforts of pharmaceutical companies and healthcare institutes who share similar aim of improving treatment & care for patients suffering from rare neurological diseases. For example, Brains for Brain Foundation, European Brain Council, LSD Patient Collaborative, and members of pharma industry are supporting an initiative in Europe which is expected to enhance visibility, awareness and recognition of rare neurological disorders for facilitating their early diagnosis. The initiative also aims to facilitate and promote collaboration and partnership between physicians, patient advocates, decision- & policy-makers, and researchers.

North America to Lead Global Rare Neurological Disease Treatment Market

North America is set to lead the global rare neurological disease treatment market, with an estimated revenue share of over 40% during 2017 to 2026. Economic and technological vigour, coupled with increasing geriatric population in the region, which is highly prone to such brain-related diseases, will influence demand for rare neurological disease treatment in North America.

The market revenue share of Europe and Asia-Pacific excluding Japan will also remain significant. However, combined revenues from the markets in these two regions will continue to be smaller than those amassed from the market in North America. Rare neurological disease treatment market in North America and Europe will record a parallel expansion through 2026, in terms of value.

Biologics to Remain Preferred Drug for Rare Neurological Disease Treatment

Biologics will continue to be the preferred drug for treatment of rare neurological diseases. Revenues from sales of biologics will account for the lion’s share of the market through the forecast period, based on drug type. However, revenues from sales of organic compounds for rare neurological disease treatment are forecast to record a relatively faster growth through 2026.

With an estimated market revenue share of nearly 60% during 2017 to 2026, Alzhiemer’s disease will continue to dominate the market, based on indication. In addition, revenues from treatment of this indication segment are likely to record the fastest rise in the market through 2026. Injectables will remain sought-after among mode of administration of drugs for treating rare neurological conditions.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6445

Since the recent past, leading pharmaceutical companies have been placing more emphasis on rare disease, with tremendous support from the government. There is a greater likelihood that effective therapeutic measures for these life threatening rare diseases will be realized in the near future. FMI’s report identifies and tracks key players influencing expansion of the rare neurological disease treatment market that include EMD Serono, Inc., Jazz Pharmaceuticals, Teva Pharmaceutical Industries Limited, Johnson & Johnson, Sanofi, Medtronic Plc, Bayer Aktiengesellschaft, and Novartis AG.

Zika Virus Testing Market is expected to reach over US$ 4,400 Mn by the end of 2020

The recent outbreak of Zika in Brazil and in the rest of Latin America, the Caribbean, the United States, Canada and various parts of Europe was caused by a more virulent viral strain from Asia. This has increased the rate of Zika virus tests being conducted worldwide. A new research report by Future Market Insights highlights the current as well as future scenario of the Zika virus testing market. This report titled ‘Zika Virus Point-of-Care Testing Market: Global Industry Analysis and Opportunity Assessment 2016 – 2020’ presents a forecast of the Zika virus testing market for the said period. The market has been analyzed on the basis of factors driving the demand for testing products, trends that are prevalent in the global market and also the restraints that may hinder market revenue growth. According to the report, the global Zika virus testing market registered a market value of over US$ 4,100 Mn in 2017, which is expected to reach over US$ 4,400 Mn by the end of 2020.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2913

Carribean Region to Dominate the Zika Virus POC Testing Market with a High Growth Rate

Point-of-Care testing including the Rapid ELISA Test and Rapid IgG/IgM Zika Virus Test have emerged as powerful diagnostic tools for screening Zika virus infections. Manufacturers are offering sophisticated diagnostic kits that help in early diagnosis of Zika virus and provide results in about 15–20 minutes or an hour. Some of the most prominent Zika prone countries experiencing contraction or very slight growth in the Zika virus POC testing market are Brazil, Puerto Rico and United States. 

This is due to the fact that probable cases for Zika dropped by more than 70% during the one year period ending in 2017. Yet countries like United States are extra conscious about the spread of Zika virus in the region. There have been many travel related cases, in which travelling from a disease free country to a place with a high prevalence of Zika infects the region. Thus, the POC testing market is not expected to take a halt any time soon. Among the major regions of the global market, Latin America is expected to lead with revenue in excess of US$ 2,400 Mn by the end of 2017. The Carribean region is anticipated to project the highest growth rate during the forecast period 2017-2020.

Leading Players Operating in the Global Market

The report includes a competitive analysis of the market structure, with information on the top companies functioning in the global market. The study highlights some of the leading companies that are projected to expand their market footprint in the coming years. Few of the key players mentioned in the report include EUROIMMUN US, Inc., Creative Diagnostics, Quest Diagnostics, Artron Laboratories Inc., and GenBody Inc.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-2913

Restraints Hindering the Growth of the Zika Virus POC Testing Market

The major factor limiting revenue growth of the Zika virus POC testing market is the inefficiency of these tests to deliver accurate results. ELISA is said to provide relatively accurate results than the rapid IgG/IgM Zika virus test. Yet companies are unable to deliver products that people can completely rely on, because of the cross-reactivity with other widely circulating virus strands such as Flavivirus, Dengue, Chikungunya and Japanese Encephalitis. Results obtained using Point-of-Care Zika diagnostic test kits are not definitive, thereby affecting revenue generation in the global Zika virus testing market. It is yet to be seen whether the intensifying competition among manufacturers will result in the production of advanced POC tests, or not. 

Dry Powder Inhaler Market Will hit at a CAGR of 4% from 2017 to 2026

According to Future Market Insights, the global market for dry powder inhaler is slated to exhibit a CAGR of nearly 4% during the forecast period (2017-2026), in terms of volume. Over 4000,000 Mn units of dry powder inhaler are pegged to be sold across the globe by 2026-end.

Challenges Regarding Varying Characteristics of Dry Powder Inhalers to Pave Opportunities for Medical Device Manufacturers

Regulatory pressures and changes in drug delivery market have driven innovation of the dry powder inhaler forward. According to the World Health Organization (WHO), nearly 300 Mn people worldwide are affected by asthma, and approximately 240 Mn from the chronic obstructive pulmonary disease (COPD). Over half of these patients combined prefer use of dry powder inhalers for treatment of their disease. These devices have depicted great potential in effective and reliable drug delivery, with novel designs ensuring the possibility to overcome future compliance, cost, and safety challenges. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-5150

Some of the essential performance characteristics regarding dry powder inhalers are associated with dose-delivery, performances at varying airflows, and fine particle fraction content. These characteristics may vary with respect to powder formulations, creating the need for fine tuning of the device or powder formulation or both combined for achieving optimal performance. The requirement is particularly high in micro-dosing dry powder inhalers, which in turn is paving opportunities for medical device manufacturers in terms of innovations and advancements.

Growing adoption of unhealthy lifestyle, increasing geriatric population, and growing air pollution levels fuelling prevalence of various respiratory disorders are key factors driving expansion of the global dry powder inhaler market. In addition, favorable government initiatives being taken across the globe for improving the healthcare infrastructure will further influence the market growth in the near future. However, the fact that dry powder inhalers are not moisture-resistant remains a major challenge for manufacturers, as the medicine loses its properties when it comes in contact with the moisture. Availability of effective alternatives such as nebulizers and electric pumps are expected to restrain adoption of dry powder inhalers. Lack of awareness regarding these devices in low-income & underdeveloped countries may further hinder the market growth to a certain extent.

Key Research Findings from FMI’s Report on Dry Powder Inhaler Market

• North America will continue to be the most lucrative region for growth of the dry powder inhaler market. Dry powder inhaler sales in the region will register the fastest expansion through 2026. Asia-Pacific excluding Japan (APEJ) is expected to be the second largest market for dry powder inhaler.
• Hospital pharmacies will continue to be the leading distribution channel for dry powder inhalers, with sales pegged to surpass 150,000 Mn units by 2026-end.
• Dry powder inhalers will continue to observe the largest application in the treatment of asthma, followed by chronic obstructive pulmonary disease. In addition, sales of dry powder inhalers for application in the treatment of asthma and pulmonary arterial hypertension are slated to exhibit a parallel growth through 2026.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-5150

Leading companies in the global dry powder inhaler market are focusing on the development of new generation products. These market players are making huge investments in R&D activities associated with novel device architectures, particle engineering, and powder formulations. Development of improved particle properties, along with efficient inhaler designs is expected to remain key strategies among the market players. Key market participants profiled in the report include Vectura Group Plc, MannKind Corporation, Chiesi Farmaceutici S.p.A., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Cipla Ltd., Novartis AG, GlaxoSmithKline Plc, 3M Company, and Astrazeneca Plc.

Cardiac Assist Devices Market is expected to reach a market value of over US$ 2,200 Mn by the end of 2027

Global Cardiac Assist Devices Market: Snapshot

A cardiac assist device is an electromechanical device for assisting cardiac circulation, which is used either partially or to completely replace the function of a failing heart. A new research report by Future Market Insights highlights the changing scenario of the global cardiac assist devices market given the increase in cases of cardiovascular diseases across the world. The report is titled ‘Cardiac Assist Devices Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027,’ and depicts the market forecast during the study period 2017-2027. This comprehensive research report indicates that the global burden of cardiovascular diseases is expected to be around 29% of the total deaths. This has increased the need for better cardiac assist devices in the market.

The global cardiac assist devices market is expected to reach a market value of over US$ 2,200 Mn by the end of 2027, growing at a CAGR of 5.7% during the forecast period. The rise in demand for cardiac assist devices is also a result of limited heart donors available across the world. The global cardiac assist devices market is also said to be highly competitive due to the presence of well-established top players in the global market. Companies are now focussing on new product launches and developing smart cardiac assist devices in order to gain maximum market share.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-467

Global Cardiac Assist Devices Market: Segmental Analysis

• Based on region, North America holds the largest market share with an expected market size of over US$ 1,100 Mn by the end of 2027. Western Europe is the second largest region in the global cardiac assist devices market in terms of value.
• On the basis of product type, the ventricular assist device segment is predicted to stay ahead with the maximum market share and fastest growth. This segment is expected to reach a market value of over US$ 1,600 Mn by the end of 2027, growing at a CAGR of 6.1% during the forecast period.
• In terms of modality, the implantable application segment is expected to lead with the highest market share and fastest growth, leaving the transcutaneous segment lagging behind in terms of market size.

• Based on end user, hospitals are expected to hold the highest market share with an estimated valuation of over US$ 1,700 Mn by the end of 2027. However, ambulatory surgical centres are expected to witness the fastest growth at the rate of 6.7% during the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-467

Global Cardiac Assist Devices Market: Competitive Landscape

This research report consists of detailed information of all the major players in the industry along with a brief profile depicting their current and future strategies. Some of these key players mentioned in the report are Thoratec Corporation, MAQUET GmbH & Co., Teleflex Incorporated, Heart Ware International, Berlin Heart GmbH, ABIOMED, SynCardia Systems, Inc., Abbott Laboratories, Medtronic Plc., Terumo Corporation etc.

Disposable Negative Pressure Wound Therapy Devices Market Analysis By 2027

In the report published by Future Market Insights titled “Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 – 2016) and Opportunity Assessment (2017 – 2027)”, it has been stated that the development around the globe in the last couple of years reflected certain complexities and fissures related to the political environment across many countries. As protectionists are threatening to penetrate the notions of free-trade, globalization is likely to face its most difficult test ever. The threat of populist policies disrupting the decades-old trade agreements have grown bigger as the social and cultural rift between the bourgeoisie and proletariat is deepening with time. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6348

While the preceding decades were marked by unison and formation of economic blocks, disintegration has been the story of the recent past. Although the business climate is far from favorable for organizations who have interest in multiple countries, the prevailing encounters have also obligated that corporate social responsibility becomes more than just a formality and companies actually demonstrate that they contribute to the societies they operate in. There is a dire need for companies to participate in discussions and debates that will eventually lead to policy formulations. Owing to these circumstances the global disposable negative pressure wound therapy devices market is anticipated to witness a CAGR of 10.6% over the forecast period of 2017 and 2027.

Cost Control Measures and Rising Healthcare Expenditure to Bode Well for the Market

The adoption rate of disposable NPWT devices is rising in developed nations such as the U.K., Germany, and the U.S., due to the obligation of healthcare burden across these countries owing to the growing prevalence of chronic wounds. According to an article on Wound Practice and Research, the healthcare expenditure for chronic wounds of 6.5 Mn patients accounts for over US$ 25 Bn per year in the U.S. Other research studies have also indicated that among chronic wounds, venous insufficiency ulcers constitute approximately 50% of the chronic leg ulcers. These wounds result due to venous etiology. Annual prevalence of venous insufficiency ulcers in those aged 65 and above has been estimated to be near to 2 in every 100 persons per year. Prevalence of pressure ulcers varies between 0.31% and 0.70% per year in the United States.  Such cases are likely to boost the demand for disposable NPWT in the years to come.

Moreover, the growing focus on the expenditure pertaining to healthcare across developed as well as developing nations is expected to drive the adoption high quality patient care treatment options across the globe. This has also led to the rise in the per capita healthcare expenditure owing to the rising disposable income of people across the globe. This, is further expected to fuel the demand for wound care therapy and also increase the adoption of disposable NPWT devices in the course of the forecast period.

North America to Lead Among All Regions

North America is expected to stay on the vanguard during the forecast period in the global disposable NPWT devices market with a share of 51.1% in the overall market. The U.S. is expected to emerge as the most lucrative nation in North America closely trailed by Western Europe and Asia Pacific excluding Japan. Based on product type, the market has been bifurcated into disposable NPWT with canister and disposable NPWT without canister. On the basis of end user, the market has been segmented into hospitals, clinics, and homecare settings.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6348

Market Players to Concentrate on Product Differentiation

The top players in the market are focusing on product differentiation and expansion of consumer base in order to retain their position in the market. The leading players accounted for over 77% of the global market share in 2016. The players are Acelity (Kinetic Concepts, Inc.), Cardinal Health Inc., Smith and Nephew PLC., ConvaTec Inc., and Medela.

Anti-Osteoporosis Therapy and Fracture Healing Market Expected to Behold a CAGR of 5.0% through 2018-2026

Future Market Insights has recently published a report titled “Anti-Osteoporosis Therapy and Fracture Healing Market: Global Industry Analysis (2012 – 2017) and Opportunity Assessment (2018 – 2026).” The report states that despite the uncertainty in terms of political and economic scenario, the global healthcare industry is expected to receive a positive push from sectors such as medical imaging, in-vitro diagnostics, biotech and pharmaceuticals, and medical devices. Key markets across the world are facing an enormous rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits. A speedily multiplying geriatric population, growing prevalence of chronic ailments such as cancer and cardiac disease, rising awareness among patients and high investments in clinical innovation are a few of the factors that are impacting the performance of the global healthcare industry at present. As a result of these factors, the global anti-osteoporosis therapy and fracture healing market is expected to witness a CAGR of 5.0% between 2018 and 2026.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1008

Growing Geriatric Population to Augur Adoption

Rising prevalence of osteoporosis is considered to be an important factor driving the global market, as the growing number of patients will also increase the demand for drugs and therapy. Furthermore, due to the absence of any substitutes such as surgery, demand for osteoporosis drugs is increasing constantly. According to the International Osteoporosis Foundation, almost 50% of the global bone fracture incidences would occur in the Asia Pacific region by 2050 end. A high occurrence and incidence rate of the disease is considered an important driver for the market. Furthermore, rising geriatric population is considered to be an important factor for the growth of the market in the coming years, although patent expiries of leading brands would considerably slow down the growth rate.

Bisphosphonates to Lead Among Drug Types

The global anti-osteoporosis therapy and fracture healing market has been segmented on the basis of drug type into bisphosphonates, calcitonin, estrogen or hormone replacement therapy, biologics, and anabolics. Among these, bisphosphonates is expected to emerge dominant by the end of 2026 with a valuation of around US$ 5,941 Mn in the same year.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1008

Companies to Fight for Patent Rights

Leading companies in the market are competing against each other to gain patent rights on the different novel drugs that are being introduced in the market. This is further expected to intensify competition in the global market in the long run. Some of the companies operating in the global anti-osteoporosis therapy and fracture healing market are Novartis, Johnson and Johnson, GlaxoSmithKline PLC, Roche, Pfizer, MERCK, and AMGEN, among others.

Healthcare Regulatory Affairs Outsourcing Market to Garner US$ 2,000 Mn by 2025

Global Healthcare Regulatory Affairs Outsourcing Market: Overview

Consistent evaluation of cost-saving options such as regulatory affairs outsourcing is carried out by several drug/device manufacturers in order to streamline their operations and ensure product safety and maintain public healthcare.

The global health care regulatory affairs outsourcing market includes services like regulatory writing and publishing, clinical trial applications, etc. A new research report by Future Market Insights provides an in-depth analysis of the global regulatory affairs outsourcing market. This comprehensive research report is titled ‘Healthcare Regulatory Affairs Outsourcing Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025’. It includes all the crucial numbers of the market along with the dynamics impacting it. According to this research report the global healthcare regulatory affairs outsourcing market is expected to reach a market revenue of over US$ 2,000 Mn by the end of 2025, growing at a stellar CAGR of 12.2% over the forecast period. The growth of the market is triggered largely by the increasing investments in the healthcare industry along with the increase in research and developments taking place. Also increasing focus on CMOs and CROs has been observed in the market. The reports also depicts that Asia Pacific is expected to lead the global healthcare regulatory affairs outsourcing market during 2017-2025. Low cost, fast turnaround time and easy availability of the skilled and trained professionals will further result in increased outsourcing in APAC countries. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6355

Global Healthcare Regulatory Affairs Outsourcing Market:  Segmental Analysis

• Based on End Users, mid-size pharmaceutical companies leads the market with a high market size expected during the forecast period, growing at a CAGR of 13.8% during the forecast period. However Biotechnology companies are also progressing at a high rate and is expected to give a strong competition to mid-size pharma companies in terms of growth rate expected during the forecast period.
• On the basis of Services, regulatory writing and publishing service segment is expected to dominate the market with a market share of over US$ 800 Mn by the end of 2025. However the segment is much behind the other services in terms of growth rate. Regulatory consulting and legal representation is the service which is expected to register fastest growth at a CAGR of 14.3% during the forecast period.
• In terms of Region, Asia Pacific is expected to be the largest region with a high market valuation. However, North America is also expected to give tough competition to APAC. Both these regions are expected to reflect a valuation higher than US$ 720 Mn by 2025 end. However North America lags behind in the race with comparatively less CAGR expected during the forecast period. Whereas, Asia Pacific is expected to register the fastest growth rate of 13.2% CAGR during the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6355

Global Healthcare Regulatory Affairs Outsourcing Market:  Competitive Landscape

The research report consists of a brief profile of all the major players leading in the industry. It also includes a SWOT analysis of these companies. The leading players mentioned in the report includes companies like Clinilabs, Inc., Accell Clinical Research, LLC.,  Freyr Solutions, The Weinberg Group Inc., Covance, Inc., (LabCorp), Pharmaceutical Product Development LLC, ICON plc., Sciformix Corporation etc.

Female Pelvic Implants Market is Poised to Exhibit A Moderate 2.8% CAGR through 2027

Female pelvic implants are surgically inserted in the vagina to treat disorders such as pelvic organ prolapse and stress urinary incontinence. These disorders are responsible for affecting the life of women to a great extent and are prevalent mostly in the older generation. The option available for treating the issue is surgical repair with or without prosthetic implants. The market is popular in different regions of the world, as this is the only available treatment option for POP and SUI. The main products involved in the implantation process are vaginal mesh implants, vaginal grafts, vaginal slings and tapes. The global female pelvic implants market registered a market value of over US$ 230 Mn in 2017, which is expected to reach a value of over US$ 300 Mn by the end of 2027. The market is anticipated to witness a sluggish CAGR of 2.8% during the forecast period.

Market Dynamics

The female pelvic implants market is projected to witness a downfall and grow at a sluggish rate, marking a few issues that are limiting the growth of market. The major issue behind the restricted growth of the market pertains to complications that are associated with female pelvic implants. The surgeries that have taken place in the past have resulted in many health related issues like mesh erosion, infections etc. However there has been a shift of countries towards the value based healthcare model, which may help the female pelvic implants market. The governments and regulatory bodies of various countries are adopting various cost-containment measures to reduce the healthcare burden, especially in developed economies. This shift from volume- to value-based system is driven by various measures taken by governments, providers, payers and life sciences companies, which include outcome-based pricing, profit and risk sharing, price control and competitive tendering. This may have a positive impact on the market in the coming years.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3422

Segmental Outlook

China is expected to be an attractive region in the global market for female pelvic implants. According to the forecast presented in this report, China will register a CAGR of 4.7% during the forecast period. However, in terms of market value, North America is anticipated to reach over US$ 80 Mn by the end of 2027. The growth of the various regional female pelvic implants markets is mainly driven by the rising geriatric population and a rise in need for optimal methods to treat pelvic organ prolapse.

In terms of indication type, stress urinary incontinence has a higher market share than pelvic organ prolapse. SUI is expected to hold a market value of over US$ 190 Mn by the end of 2027, growing at a CAGR of 3.6% during the forecast period. There is a significant rise in the rate of women suffering from SUI worldwide.

Competitive Scenario

With the rapidly changing dynamics of the female pelvic implants market, many companies are hesitating in taking risks. Manufacturers in the global market have faced over 650 lawsuits alleging a host of painful device related injuries. Such complications during the process of implants have resulted in many major companies exiting the market. There is however, hope for market players in developing regions where implant procedures are still prevalent. The companies who have exited the global market include Betatech, AMS, Promedon, Aspide Medical etc. On the other hand, companies that continue to prevail in the global market include Coloplast, Boston Scientific, PFM Medical, Ethicon, etc.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3422

The upcoming years will show whether the various legislations and product developments will come up as a savior for the remaining players in the global female pelvic implants market.

Vulvodynia Treatment Market to Surpass US$ 8,091.6 Mn by 2028

Future Market Insights (FMI) has published a new research report on vulvodynia treatment market. The report has been titled, “Vulvodynia Treatment Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028.”  The report states that a recent Harvard study showed that there are approximately 6 million American women who are suffering from vulvodynia. Over 60% of patients’ report of visiting three or more health care providers for diagnosis and an astonishing 40% of patients remain undiagnosed. This study also reported that 40% of women with painful symptoms did not even seek medical care. Associations such as the National Vulvodynia Association (NVA) are playing a vital role in spreading awareness regarding Vulvodynia treatment. The NVA announced the launch of “Indivisible: Breaking the Silence”, a campaign empowering women with vulvodynia to break their silence and improve the path to diagnosis and treatment.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-4985

In order to cater to the need of the growing number of patients, companies are looking out for treatments and drugs that can subside the pain related to vulvodynia. Towards this, they are investing in research and development and mergers and acquisitions. For instance, in January 2016, Merck & Co. Inc., acquired IOmet Pharma Ltd., a privately held U.K.-based drug discovery company focused on the development of innovative medicines for the treatment of cancer. The other leading companies operating in the market are Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan plc, among others.

According to the report, the global vulvodynia treatment market is expected to register a CAGR of 6.1% over the forecast period of 2018 and 2028. The market was worth US$ 4,261.2 Mn in 2017 and is expected to rise to a valuation of US$ 8,091.6 Mn by the end of 2028.

Growing Adoption to Augur Well for Global Market Revenue Growth

The swelling number of patients suffering from vulvodynia and harsh nature of chronic vulvar pain have led to the adoption of early diagnosis and treatment. The adequate results of medical treatments such as drugs, injections and creams have increased the preference for medication to treat vulvodynia. Furthermore, increasing adoption of medicinal treatments of vulvodynia has resulted in an increase in the sales of hormones, local anesthetics, and antidepressants. Additionally, promising compensation policies in most of the developed countries are also expected to act as a value driver to the growth of the global vulvodynia treatment market. On the other hand, the growing prevalence of the vulvodynia disease among women across the globe is a core factor that is pushing the growth of the vulvodynia treatment market. Vulvodynia is a very common disease in the United States and across the globe. Nevertheless, the ailment remains underdiagnosed or in some cases also incompetently treated.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-4985

Lethargic Research and Development for Vulvodynia Treatment Drugs to Slow Down Market Growth

Owing to the absenteeism of detailed information by patients, ignorance of the cause of vulvar pain, and satisfactory results of anticonvulsants and tricyclic antidepressants, researchers are unable to unveil the exact cause of vulvodynia and thereby the R&D on vulvodynia drugs is limited. After anticonvulsants and tricyclic antidepressants, only serotonin and norepinephrine reuptake inhibitors (SNRIs) drugs have showed positive results. Furthermore, if observed, the research and development for vulvodynia treatment is also in a very sluggish phase.

Varicella Zoster Infection Treatment Market to Reach a Valuation of US$ 1,969.1 Mn By 2027

Future Market Insights (FMI) has published a new report on the varicella zoster infection treatment market titled “Varicella Zoster Infection Treatment Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027.” Varicella zoster infection comprises two main types namely varicella chickenpox and herpes zoster. Varicella is a highly contagious infection with an incubation period of 10–21 days, most commonly 14–16 days, after which characteristic rashes appear. Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, haemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6466

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorised by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population. Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications. In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.

For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Per the agreement Novartis obtained the sales and marketing rights, which increased their position in the market. Other leading companies operating in the market are Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Abbott Laboratories, GlaxoSmithKline Plc., and Dr. Reddy’s Laboratories Ltd., among others.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well. These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6466 

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Herpes Labialis Treatment Market will possibly reach beyond US$ 1.3 Bn by the end of 2027

Attributed to rising penetration of generics and innovations in disease treatment, the US$ 869.3 Mn global herpes labialis treatment market is anticipated to expand at a CAGR of 4.6% over 2017-2027, attaining a value worth US$ 1,358.7 Mn by 2027 end. Over a 10-year forecast period, the demand for herpes labialis treatment is likely to be driven by growing instances of viral infection worldwide and evolution of drug types and modes of action. Moreover, strategic M&A activities among leading industry players as well as amplifying investments in R&D ventures will also turn out to be profitable for the global herpes labialis treatment market during the assessment period.

North America to Maintain Leading Regional Market Position

Supported by strong presence of a few of the key industry players, North America’s herpes labialis treatment market is expected to continue its dominance throughout the forecast period. While this region registered over 35% value share, Western Europe recorded a share of over 20% in 2017. North American region is presumed to exceed the revenues worth US$ 450 Mn by the end of 2027, observing a declining CAGR of 3.9%. Although the US will lead the North American region, Future Market Insights projects that Canada will witness higher adoption of herpes labialis treatment in the assessment period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6461

On the flipside, emerging regional markets such as APEJ, MEA, Eastern Europe, and Latin America will see rapid growth in the forecast period. APEJ is identified to be the fastest growing market at a promising CAGR of 5.7%, followed by MEA, predicted to grow at 5.3% CAGR over 2017-2027. Strengthening efforts and accelerating investments in the examination of the clinical efficacy of drugs, increasing expenditure on R&D infrastructure, growing consumer awareness, and development of advanced, cost-effective treatment options at a rapid pace, will collectively lift the market in emerging countries up. Moreover, lenient FDI policies that govern the pharmaceuticals industry in developing economies prompt at the inflow of a series of opportunities for drug companies to explore these regional markets in near future.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6461

Key Market Players

Some of the leading players competing in the global herpes labialis treatment market include Novartis AG, Valeant Pharmaceuticals International Inc., Pfizer Inc., Abbott Laboratories, Mylan NV, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc. A majority of key players are directing their efforts towards extension of existing product portfolio, while others are focusing on strategic mergers and acquisitions in order to grab larger market shares in terms of revenue. Many top brands are looking forward to capitalize on growing opportunities in emerging regional markets.

Gynaecological Examination Chairs Market Estimated to Exhibit 6.9% CAGR through 2028

With the growing income of people across the globe, they are willing to pay more for healthcare, the revenue being generated by hospitals is also increasing rapidly. Hospitals and various healthcare facilities are also increasing their spending to enhance the quality of services and their equipment. The proliferating healthcare expenditure is expected to positively impact the gynaecological examination chairs market.

As a result of the growing demand and expenditure of the consumers, companies are also gearing up in order to take leverage of the arising opportunities and to stay competent in the market. They are strengthening product portfolio by launching novel products with advanced features through product development and acquisitions and mergers. The companies are also concentrating on developing a strong distribution channel and supplier chain in order to expand their presence in the emerging and untapped markets. For instance, in May 2017, Oakworks Inc. announced the introduction of STUDIO, a table designing solution that provides clients with complete flexibility when designing products. Along this line in the same time, the company completed the collaboration with FAMED Medical Solutions. Due to collaboration the company introduce novel iNSPIRITMedical Solutions.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6750 

According to a report published by Future Market Insights (FMI), the global gynaecological examination chairs market is expected to witness a CAGR of 6.9% from 2018 to 2028. The market was worth US$ 408.4 Mn in 2017 and is projected to rise to a valuation of US$ 852.3 Mn by the end of 2028.

Advances in Technology to Have a Positive Impact on the Market

The healthcare industry around the globe is booming exponentially. Heavy investments are made in the healthcare industry, especially in the hospital and clinics sectors. The demand for technologically advanced products is increasing among practitioners and physicians for reducing operating and examination time. Adoption of technologically advanced chairs powered by foot switches and remote will be beneficial in adjusting the required height. These advance features provide efficiency in examination. Gynaecologists across the globe are adopting advanced gynaecological chairs that are compatible with video colposcopy device holders, organic waste containers and are made of antimicrobial materials in order to reduce the time and manpower required to manage all the adjustments.

Strict Regulations to Act as a Prime Roadblock in Market Growth

The companies in the market are facing strict regulatory policies in the development of new products for medical furniture, such as examination chairs and tables. The manufactured products should meet the standards of the U.S. Access Board Proposed Standards for Accessible Medical Diagnostic Equipment. Most of the companies are facing difficulties in bringing gynaecology examination chairs to the market without greater predictability and transparency from FDA. The products have to meet the standard of sterilization and environment protection regulation.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-6750

Meningococcal Vaccines Market to Cross US$ 6,008.9 Mn by 2028

Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives. The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need. The governments of several countries across the globe initiate immunisation programmes periodically and these programmes are backed by global organisations such as UNICEF and WHO and private not for profits like the Global Alliance for Vaccines and Immunization (GAVI).

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1252 

A classic example of how private-public partnerships are helping boost vaccination programmes across deep regional pockets is Brazil. In 2010, Ezequiel Dias Foundation, Brazil formed a strategic alliance with Novartis Vaccines & Diagnostics for the sustainable supply of Menjugate MenC vaccines for Brazil’s National Immunization Program. By 2015, Brazil became self-sufficient in the production of the meningococcal C conjugated vaccine for the country’s public vaccination programmes. Such initiatives at the global level are anticipated to support global immunisation goals and at the same time boost growth of the meningococcal vaccines market.

Factors Leading to Worldwide Adoption of Meningococcal Vaccination Programmes

The global meningococcal vaccines market is expected to be driven by enhanced access to vaccines in low and middle-income countries, growing investments by manufacturers and governments to cope with pandemic meningitis outbreaks, and rapidly growing consumption of meningococcal vaccines bolstered by immunisation alliances and mass vaccination campaigns among others. Partnerships and alliances between manufacturers and governmental healthcare organisations are facilitating the speedy introduction of vaccines in some of the economically challenged countries of the Middle East and Africa region. Enhanced access to vaccines in under-penetrated global markets is expected to accelerate revenue growth of the global meningococcal vaccines market.

Approval of new vaccines in the U.S and Europe in 2015 and 2017 to treat meningococcal meningitis has revolutionised the global immunisation landscape. This is further boosting the growth trajectory of the global market for meningococcal vaccines.

According to Future Market Insights projections, the global market for meningococcal vaccines is expected to reach US$ 6,008.9 Mn by 2028 end from a valuation of US$ 2,290.7 Mn in 2017 – reflecting a CAGR of 9.2% during the 10 year period from 2018 to 2028.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1252 

GlaxoSmithKline to Lead the Global Meningococcal Vaccines Market with About 50% Market Share Recorded in 2017

The global meningococcal vaccines market is highly consolidated, with GlaxoSmithKline and Sanofi together holding about 80% of the global market share in 2017. Pfizer is the third largest company in this market with just under 12% market share in 2017. Companies are expanding their production capacities through the acquisition of established vaccines production units of other global or local companies. Sanofi has a huge pipeline of 17 active meningococcal vaccines programmes and is targeting emerging markets; while GlaxoSmithKline has 5 active pipeline programmes for meningococcal vaccines, all of which are in the phase II clinical stage. Addition of the vaccine Bexsero has enabled GlaxoSmithKline to defend its brand against Sanofi’s aggressive portfolio in the paediatric vaccines space.